Risk of cardiovascular disease in patients with multiple sclerosis treated with fingolimod compared to natalizumab: A nationwide cohort study of 2095 patients in Denmark

• Published in: Multiple sclerosis p. 13524585231221415
• Main Authors: Framke, Elisabeth, Thygesen, Lau Caspar, Malmborg, Morten, Schou, Morten, Sellebjerg, Finn, Magyari, Melinda
• Format: Journal Article
• Language: English
• Published: England 01.02.2024
• Subjects: CVD; cardiovascular disease; adverse events; Fingolimod; multiple sclerosis; safety
• ISSN: 1477-0970
• DOI: 10.1177/13524585231221415

Fingolimod may be associated with risk of developing cardiovascular disease (CVD). Studies including reference groups and long follow-up are scarce. We hypothesized that patients treated with fingolimod would be at higher risk of developing CVD compared to patients treated with natalizumab. A nationwide 12-year cohort study linking individual-level data from the Danish Multiple Sclerosis Registry with health registries on 2095 adult patients with multiple sclerosis (MS) without any health records of CVD at follow-up start. Exposure to fingolimod and natalizumab was defined by the first treatment of at least 3 months. Cohort entry was from 2011 to 2018. We defined CVD as a composite measure, including hypertension, ischemic heart disease, atrial fibrillation, heart failure, and stroke. We used multivariable adjusted Cox regression. There were 28.8 and 17.4 CVD events per 1000 person-years in fingolimod and natalizumab groups, respectively. Compared to natalizumab-treated patients, fingolimod-treated patients had a higher risk of CVD (hazard ratio (HR) = 1.57; 95% confidence interval (CI) = 1.18-2.08). Hypertension comprised 200 of 244 CVD events. We found an increased risk of CVD in patients with MS treated with fingolimod. This increased risk was mainly due to hypertension.